505 related articles for article (PubMed ID: 29496986)
1. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
[TBL] [Abstract][Full Text] [Related]
2. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
[TBL] [Abstract][Full Text] [Related]
3. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
5. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
6. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
[TBL] [Abstract][Full Text] [Related]
8. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
9. First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs).
Merkul E; Sijbrandi NJ; Muns JA; Aydin I; Adamzek K; Houthoff HJ; Nijmeijer B; Van Dongen GAMS
Expert Opin Drug Deliv; 2019 Aug; 16(8):783-793. PubMed ID: 31327255
[No Abstract] [Full Text] [Related]
10. A Systematic Evaluation of Antibody Modification and
Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW
Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571
[TBL] [Abstract][Full Text] [Related]
11. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
12. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.
Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ
Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250
[TBL] [Abstract][Full Text] [Related]
13. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
14.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
15. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.
Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC
Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847
[TBL] [Abstract][Full Text] [Related]
16. Bioorthogonal Fluorophore Linked DFO-Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies.
Meimetis LG; Boros E; Carlson JC; Ran C; Caravan P; Weissleder R
Bioconjug Chem; 2016 Jan; 27(1):257-63. PubMed ID: 26684717
[TBL] [Abstract][Full Text] [Related]
17. Light-Induced Radiosynthesis of
Klingler S; Fay R; Holland JP
J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
[TBL] [Abstract][Full Text] [Related]
18.
Dias GM; Ramogida CF; Rousseau J; Zacchia NA; Hoehr C; Schaffer P; Lin KS; Bénard F
Nucl Med Biol; 2018 Mar; 58():1-7. PubMed ID: 29291493
[TBL] [Abstract][Full Text] [Related]
19. An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt
Merkul E; Muns JA; Sijbrandi NJ; Houthoff HJ; Nijmeijer B; van Rheenen G; Reedijk J; van Dongen GAMS
Angew Chem Int Ed Engl; 2021 Feb; 60(6):3008-3015. PubMed ID: 33185916
[TBL] [Abstract][Full Text] [Related]
20. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
